It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

CEO Stéphane Bancel laid out a plan to reverse that. Moderna CEO Stéphane Bancel said in his 2024 shareholder letter published Monday that the past year brought "formidable challenges" for the ...

One of the closest-to-market among the 10 is mRNA-1283, a next-generation COVID vaccine. In his Monday letter, Bancel said the FDA has accepted Moderna’s application for the shot. Assisted by a ...

The coronavirus will never disappear, Moderna CEO Stephan Bancel said during a panel earlier this week. “We are going to live with this virus, we think, forever,” he said. Separately ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna Inc. entered the new year on the ... Subscribe to our free Morning Edition and Afternoon Edition email newsletters. CEO Stéphane Bancel cited several factors for the updated figures ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Shares plunge more than 24% in early trading 2025 revenue forecast misses expectations, prior view CEO Bancel says to reduce 2025 cash costs by $1 bln Jan 13 (Reuters) - Moderna (MRNA.O), opens ...

It expects to end 2025 with a cash balance of $6 billion. Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Moderna lost more than 20% of its value ... stressing savings as key to its goal of balancing cash flow by 2028. Ahead of CEO Stéphane Bancel’s address at the JP Morgan Healthcare Conference ...